...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Clinical trials site

There was an update to the site posted today for the ph2b trial for triple-negative breast cancer - recruiting has begun

Share
New Message
Please login to post a reply